NCT01960504View on ClinicalTrials.gov

First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)

NAUnknownINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

May 31, 2020

Conditions
Coronary Artery DiseaseCoronary Artery Stenosis
Interventions
DEVICE

Percutaneous Coronary Intervention (DREAMS) stenting

Trial Locations (13)

1011

CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne

8200

Aarhus University Hospital, Aarhus

9300

OLV-Ziekenhuis Aalst, Aalst

28040

Hospital Clinico San Carlos, Madrid

41464

Städtische Kliniken Neuss - Lukaskrankenhaus, Neuss

79189

Universitäts-Herzzentrum Freiburg Bad Krozingen, Bad Krozingen

168752

National Heart Centre Singapore, Mistri Wing

04012-909

Instituto Dante Pazzanese de Cardiologia, São Paulo

05403-000

Instituto do Coração - HCFMUSP, São Paulo

D-23795

Segeberg Kliniken GmbH, Herzzentrum, Bad Segeberg

Unknown

Vivantes Klinikum, Berlin

7513ER

Thoraxcentrum Twente, Enschede

CH-4031

University Hospital Basel, Basel

Sponsors

Lead Sponsor

Biotronik AG
All Listed Sponsors
lead

Biotronik AG

INDUSTRY

NCT01960504 - First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II) | Biotech Hunter | Biotech Hunter